Menü
The United States Food and Drug Administration (FDA) has approved the next generation SynchroMed III intrathecal drug delivery system (intrathecal pain pump) for patients with chronic pain, cancer pain and severe spasticity.
On October 10, 2023, Medtronic announced that the SynchroMed™ III intrathecal drug delivery system has been approved by the FDA for chronic pain, cancer pain and severe spasticity. Medtronic plc, headquartered in Dublin, Ireland, is the world’s leading healthcare technology company, boldly tackling the most challenging health issues facing humanity by researching and finding solutions.
SynchroMed III delivers medication directly into the fluid surrounding the spinal cord through a catheter connected to a small, battery-operated programmable pump. Intrathecal drug delivery (intrathecal pain pump) therapy is more effective than systemic drugs in treating chronic pain, cancer pain or severe spasticity, with fewer side effects and is both safe and effective to administer under the supervision of a physician.
Patients implanted with the SynchroMed III system will be able to undergo diagnostic imaging procedures using 1.5 and 3 Tesla magnetic resonance imaging (MRI) devices if necessary.
